Randomized controlled trials (RCTs) using PARP inhibitors or platinum for treating patients with metastatic, locally advanced, or recurrent breast cancer carrying BRCA1/2 pathogenic variants have shown efficacy, as evidenced by improved survival duration (13–15). Here, BRCA1 is linked to breast cancer.